$0.178
+0.056 (+31.56%)Al cierre
Noticias de SGMO
Eventos de SGMO
Sangamo Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Reorganization
Sangamo Therapeutics (SGMO) announced that it has commenced voluntary Chapter 11 bankruptcy reorganization proceedings and entered into separate "stalking horse" asset sale agreements with Eli Lilly (LLY) and Astellas Pharma (ALPMF). Under the agreements, Lilly will bid for Sangamo's genomic platforms and prion disease program, while Astellas will bid for its Fabry disease program. The company has secured a commitment for debtor-in-possession financing from Northridge ATM, LLC to support its operations through the court-supervised auction and restructuring process. "Following a comprehensive review of available alternatives, we believe this process provides a clear framework to pursue value-maximizing transactions," said Sandy Macrae, CEO of Sangamo Therapeutics. "Our priority is to execute a disciplined and efficient sale process while supporting all of our stakeholders. We are also pleased to have signed agreements with two large pharmaceutical companies to serve as stalking horse bidders in the process, underscoring the strategic interest in our assets."
Company's Financial Guidance Depends on Securing Additional Funding
The company said, "This financial guidance is subject to our ability to secure adequate additional funding for our current operating plan."
Sangamo Reports Q4 Revenue of $14.23M
Reports Q4 revenue $14.23M vs. $7.55M last year. "Sangamo continued to make significant pipeline progress since the start of 2025. Following positive topline results from our registrational STAAR study in Fabry disease, we are well advanced in the rolling submission of the BLA to the FDA under the Accelerated Approval pathway," said Sandy Macrae, CEO of Sangamo. "In 2025, we also became a clinical-stage neurology company, with recruitment having commenced in the Phase 1/2 STAND study in small fiber neuropathy, and we continued to demonstrate that we are a collaborator of choice for neurotropic capsids, with the announcement of our third STAC-BBB capsid license agreement."
Sangamo Submits ST-920 for Accelerated Approval
Sangamo Therapeutics announced advancement of the rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920. Following initiation of the rolling submission in December 2025, Sangamo has now submitted the preclinical and clinical modules to the FDA for review. Rolling submission allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis rather than waiting for the entire BLA to be submitted at once. In addition, the antibody assay companion diagnostic, which is designed to screen patients for eligibility with isaralgagene civaparvovec, has been submitted to, and accepted by, the FDA's Center for Devices and Radiological Health seeking Premarket Approval.
Sangamo Therapeutics Prices 35.19M Share Offering at $25M
Sangamo Therapeutics announced the pricing of an underwritten offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.4719. The combined offering price of each pre-funded warrant and accompanying warrant is $0.4619. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $0.4719 per share, will become exercisable six months from the date of issuance and will expire five and a half years from the date of issuance. In addition, Sangamo agreed to reduce the exercise price on outstanding warrants to purchase 23,809,523 shares of common stock held by an investor from $1.00 to $0.4719 and extend the term of such warrants to five and a half years from the date of issuance of the securities in the offering, with such warrants to become exercisable six months from the date of issuance of the securities in the offering. All of the securities in the offering are to be sold by Sangamo. The offering is expected to close on or about February 4, subject to the satisfaction of customary closing conditions. The gross proceeds to Sangamo from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $25M. Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.